Analyses of a Ceftazidime-Avibactam-Resistant <italic toggle="yes">Citrobacter freundii</italic> Isolate Carrying <italic toggle="yes">bla</italic><sub>KPC-2</sub> Reveals a Heterogenous Population and Reversible Genotype

ABSTRACT A blaKPC-2-carrying Citrobacter freundii isolate developed ceftazidime-avibactam resistance during treatment with this agent. The initial and follow-up isolates exhibited ceftazidime-avibactam MICs of 4 and 64 µg/ml, respectively. Overexpression of AcrAB-TolC and porin alterations were dete...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mariana Castanheira, S. J. Ryan Arends, Andrew P. Davis, Leah N. Woosley, Amira A. Bhalodi, Shawn H. MacVane
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2018
Materias:	Citrobacter freundii β-lactams ceftazidime-avibactam resistance mechanism Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/03baac5888cf4fe3a5024e729a3b03a1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:03baac5888cf4fe3a5024e729a3b03a1
record_format	dspace
spelling	oai:doaj.org-article:03baac5888cf4fe3a5024e729a3b03a12021-11-15T15:22:26ZAnalyses of a Ceftazidime-Avibactam-Resistant <italic toggle="yes">Citrobacter freundii</italic> Isolate Carrying <italic toggle="yes">bla</italic><sub>KPC-2</sub> Reveals a Heterogenous Population and Reversible Genotype10.1128/mSphere.00408-182379-5042https://doaj.org/article/03baac5888cf4fe3a5024e729a3b03a12018-10-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mSphere.00408-18https://doaj.org/toc/2379-5042ABSTRACT A blaKPC-2-carrying Citrobacter freundii isolate developed ceftazidime-avibactam resistance during treatment with this agent. The initial and follow-up isolates exhibited ceftazidime-avibactam MICs of 4 and 64 µg/ml, respectively. Overexpression of AcrAB-TolC and porin alterations were detected in both isolates, but no other resistance mechanism was observed. After passaging the initial clinical isolate in ceftazidime-avibactam at a fixed concentration of 4 µg/ml and a 4:1 ratio, resistance to all β-lactams was noted, and a percentage of the blaKPC-2 sequencing reads had mutations leading to the alterations D176Y (blaKPC-2-D176Y [78%]) or R164S plus P147L (blaKPC-2-R164S + P147L [82%]). Further investigation of the follow-up isolate showed that 11% of the blaKPC-2 reads had mutations leading to D179Y substitution (blaKPC-2-D179Y). In the absence of selective pressure, ceftazidime-avibactam MICs of the passaged and follow-up isolates revealed that 7 or 8 out of 20 screened colonies reverted to susceptible and possessed blaKPC-2 wild-type sequences. Recombinant plasmids carrying the blaKPC-2 alterations observed were transformed in Escherichia coli, and MIC values for ceftazidime ± avibactam were elevated. Lower MICs for ceftriaxone, cefepime, aztreonam, meropenem, and imipenem for the mutated KPC-2-producing isolates were observed compared to those of the isolates producing a wild-type KPC-2. Avibactam at a fixed concentration of 4 µg/ml restored the activity of all β-lactams tested for the recombinant strains. The heterogenous population of wild-type and mutated blaKPC-2 and the reversibility of the genotypes observed suggest a significant challenge for managing KPC-producing isolates that develop ceftazidime-avibactam resistance during therapy. IMPORTANCE The development of ceftazidime-avibactam resistance among KPC-producing isolates during treatment with this agent has been reported. Usually isolates that become resistant have a mutated blaKPC gene that confers resistance to ceftazidime-avibactam and susceptibility to meropenem. We report a Citrobacter freundii isolate that developed ceftazidime-avibactam resistance due to mutations within the coding region of the blaKPC-2 Ω-loop previously reported; however, in this case, only 11% of the whole-genome sequencing reads had mutations, making this alteration difficult to detect and the treatment of these isolates more challenging. In addition to blaKPC, the initial and the follow-up patient isolates displayed hyperexpression of the AcrAB-TolC efflux system and disruption of the outer membrane protein (OMP) OmpF, which contribute to carbapenem resistance. Experiments performed to confirm our findings included generating mutant isolates from the initial patient isolate, passaging the isolates for purity in drug-free medium, resulting in a reversible phenotype, and cloning the mutations to demonstrate the resistance conferred.Mariana CastanheiraS. J. Ryan ArendsAndrew P. DavisLeah N. WoosleyAmira A. BhalodiShawn H. MacVaneAmerican Society for MicrobiologyarticleCitrobacter freundiiβ-lactamsceftazidime-avibactamresistance mechanismMicrobiologyQR1-502ENmSphere, Vol 3, Iss 5 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Citrobacter freundii β-lactams ceftazidime-avibactam resistance mechanism Microbiology QR1-502
spellingShingle	Citrobacter freundii β-lactams ceftazidime-avibactam resistance mechanism Microbiology QR1-502 Mariana Castanheira S. J. Ryan Arends Andrew P. Davis Leah N. Woosley Amira A. Bhalodi Shawn H. MacVane Analyses of a Ceftazidime-Avibactam-Resistant <italic toggle="yes">Citrobacter freundii</italic> Isolate Carrying <italic toggle="yes">bla</italic><sub>KPC-2</sub> Reveals a Heterogenous Population and Reversible Genotype
description	ABSTRACT A blaKPC-2-carrying Citrobacter freundii isolate developed ceftazidime-avibactam resistance during treatment with this agent. The initial and follow-up isolates exhibited ceftazidime-avibactam MICs of 4 and 64 µg/ml, respectively. Overexpression of AcrAB-TolC and porin alterations were detected in both isolates, but no other resistance mechanism was observed. After passaging the initial clinical isolate in ceftazidime-avibactam at a fixed concentration of 4 µg/ml and a 4:1 ratio, resistance to all β-lactams was noted, and a percentage of the blaKPC-2 sequencing reads had mutations leading to the alterations D176Y (blaKPC-2-D176Y [78%]) or R164S plus P147L (blaKPC-2-R164S + P147L [82%]). Further investigation of the follow-up isolate showed that 11% of the blaKPC-2 reads had mutations leading to D179Y substitution (blaKPC-2-D179Y). In the absence of selective pressure, ceftazidime-avibactam MICs of the passaged and follow-up isolates revealed that 7 or 8 out of 20 screened colonies reverted to susceptible and possessed blaKPC-2 wild-type sequences. Recombinant plasmids carrying the blaKPC-2 alterations observed were transformed in Escherichia coli, and MIC values for ceftazidime ± avibactam were elevated. Lower MICs for ceftriaxone, cefepime, aztreonam, meropenem, and imipenem for the mutated KPC-2-producing isolates were observed compared to those of the isolates producing a wild-type KPC-2. Avibactam at a fixed concentration of 4 µg/ml restored the activity of all β-lactams tested for the recombinant strains. The heterogenous population of wild-type and mutated blaKPC-2 and the reversibility of the genotypes observed suggest a significant challenge for managing KPC-producing isolates that develop ceftazidime-avibactam resistance during therapy. IMPORTANCE The development of ceftazidime-avibactam resistance among KPC-producing isolates during treatment with this agent has been reported. Usually isolates that become resistant have a mutated blaKPC gene that confers resistance to ceftazidime-avibactam and susceptibility to meropenem. We report a Citrobacter freundii isolate that developed ceftazidime-avibactam resistance due to mutations within the coding region of the blaKPC-2 Ω-loop previously reported; however, in this case, only 11% of the whole-genome sequencing reads had mutations, making this alteration difficult to detect and the treatment of these isolates more challenging. In addition to blaKPC, the initial and the follow-up patient isolates displayed hyperexpression of the AcrAB-TolC efflux system and disruption of the outer membrane protein (OMP) OmpF, which contribute to carbapenem resistance. Experiments performed to confirm our findings included generating mutant isolates from the initial patient isolate, passaging the isolates for purity in drug-free medium, resulting in a reversible phenotype, and cloning the mutations to demonstrate the resistance conferred.
format	article
author	Mariana Castanheira S. J. Ryan Arends Andrew P. Davis Leah N. Woosley Amira A. Bhalodi Shawn H. MacVane
author_facet	Mariana Castanheira S. J. Ryan Arends Andrew P. Davis Leah N. Woosley Amira A. Bhalodi Shawn H. MacVane
author_sort	Mariana Castanheira
title	Analyses of a Ceftazidime-Avibactam-Resistant <italic toggle="yes">Citrobacter freundii</italic> Isolate Carrying <italic toggle="yes">bla</italic><sub>KPC-2</sub> Reveals a Heterogenous Population and Reversible Genotype
title_short	Analyses of a Ceftazidime-Avibactam-Resistant <italic toggle="yes">Citrobacter freundii</italic> Isolate Carrying <italic toggle="yes">bla</italic><sub>KPC-2</sub> Reveals a Heterogenous Population and Reversible Genotype
title_full	Analyses of a Ceftazidime-Avibactam-Resistant <italic toggle="yes">Citrobacter freundii</italic> Isolate Carrying <italic toggle="yes">bla</italic><sub>KPC-2</sub> Reveals a Heterogenous Population and Reversible Genotype
title_fullStr	Analyses of a Ceftazidime-Avibactam-Resistant <italic toggle="yes">Citrobacter freundii</italic> Isolate Carrying <italic toggle="yes">bla</italic><sub>KPC-2</sub> Reveals a Heterogenous Population and Reversible Genotype
title_full_unstemmed	Analyses of a Ceftazidime-Avibactam-Resistant <italic toggle="yes">Citrobacter freundii</italic> Isolate Carrying <italic toggle="yes">bla</italic><sub>KPC-2</sub> Reveals a Heterogenous Population and Reversible Genotype
title_sort	analyses of a ceftazidime-avibactam-resistant <italic toggle="yes">citrobacter freundii</italic> isolate carrying <italic toggle="yes">bla</italic><sub>kpc-2</sub> reveals a heterogenous population and reversible genotype
publisher	American Society for Microbiology
publishDate	2018
url	https://doaj.org/article/03baac5888cf4fe3a5024e729a3b03a1
work_keys_str_mv	AT marianacastanheira analysesofaceftazidimeavibactamresistantitalictoggleyescitrobacterfreundiiitalicisolatecarryingitalictoggleyesblaitalicsubkpc2subrevealsaheterogenouspopulationandreversiblegenotype AT sjryanarends analysesofaceftazidimeavibactamresistantitalictoggleyescitrobacterfreundiiitalicisolatecarryingitalictoggleyesblaitalicsubkpc2subrevealsaheterogenouspopulationandreversiblegenotype AT andrewpdavis analysesofaceftazidimeavibactamresistantitalictoggleyescitrobacterfreundiiitalicisolatecarryingitalictoggleyesblaitalicsubkpc2subrevealsaheterogenouspopulationandreversiblegenotype AT leahnwoosley analysesofaceftazidimeavibactamresistantitalictoggleyescitrobacterfreundiiitalicisolatecarryingitalictoggleyesblaitalicsubkpc2subrevealsaheterogenouspopulationandreversiblegenotype AT amiraabhalodi analysesofaceftazidimeavibactamresistantitalictoggleyescitrobacterfreundiiitalicisolatecarryingitalictoggleyesblaitalicsubkpc2subrevealsaheterogenouspopulationandreversiblegenotype AT shawnhmacvane analysesofaceftazidimeavibactamresistantitalictoggleyescitrobacterfreundiiitalicisolatecarryingitalictoggleyesblaitalicsubkpc2subrevealsaheterogenouspopulationandreversiblegenotype
_version_	1718427988710653952

Analyses of a Ceftazidime-Avibactam-Resistant <italic toggle="yes">Citrobacter freundii</italic> Isolate Carrying <italic toggle="yes">bla</italic><sub>KPC-2</sub> Reveals a Heterogenous Population and Reversible Genotype

Ejemplares similares